Bill introduced
Lobbying filed by AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)
Lobbying filed by AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC
Lobbying filed by ASTELLAS PHARMA US, INC.
Lobbying filed by AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC
Committee on Health, Education, Labor, and Pensions. Hearings held.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
| Registrant | Client | Amount | Filed | Period | Issues |
|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | $4.8M | Apr 21, 2025 | 2025Q1 | HCRMMMINS |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | $2.6M | Jul 21, 2025 | 2025Q2 | HCRTAXTOB |
The lobbying table lists Senate LDA quarterly reports (LD-2) that cite this bill by number and cover a quarter of the 119th Congress. An LD-2 names a bill as “H.R. 1234” with no Congress, so a report on another Congress, which can only concern a different bill with the same number, is left out, even when it was filed after this Congress began. The amount is what the registrant reported for the whole filing, across every issue on it, not spending on this bill. Official actions and the bill summary come from Congress.gov, and votes from the roll-call record. This page no longer pairs the bill with members' stock trades: matching lobbying clients to traded companies by name, and trades to a bill by date, is not something the records establish.
Lobbying filed by ASTELLAS PHARMA US, INC.
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC |
| $2.0M |
| Apr 21, 2025 |
| 2025Q1 |
HCRTAXTOB |
| ASTELLAS PHARMA US, INC. | ASTELLAS PHARMA US, INC. | $670.0K | Jul 21, 2025 | 2025Q2 | MMMHCRCPT |
| ASTELLAS PHARMA US, INC. | ASTELLAS PHARMA US, INC. | $560.0K | Apr 21, 2025 | 2025Q1 | MMMHCRCPT |
| DANA-FARBER CANCER INSTITUTE | DANA-FARBER CANCER INSTITUTE | $92.0K | Jul 15, 2025 | 2025Q2 | BUDHCRMMM |
| DANA-FARBER CANCER INSTITUTE | DANA-FARBER CANCER INSTITUTE | $77.7K | Apr 16, 2025 | 2025Q1 | BUDHCRMMM |
| THE MCMANUS GROUP | DENDREON PHARMACEUTICALS LLC | $30.0K | Jul 21, 2025 | 2025Q2 | MMMHCR |
| THE MCMANUS GROUP | DENDREON PHARMACEUTICALS LLC | $30.0K | Apr 21, 2025 | 2025Q1 | HCRMMM |